Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
-
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
-
Mots clés
Cancer bronchique non à petites cellules
Nivolumab
Chemoresistance
AML
Systemic therapy
Radiofrequency ablation
Cemiplimab
Langerhans cell histiocytosis
Anti-PD-1 antibody
Non-small cell lung cancer
BRAF V600-mutation
Surgical excision
Survival
Immunohistochemistry
ACTH
Adjuvant therapy
Abscopal effect
Gastric bypass
2-chlorodeoxyadenosine
Colorectal cancer
Safety
Staging
Abscopal effect colorectal cancer intratumoral immunotherapy liver metastases radiofrequency
Biomarker
Crizotinib
Diagnosis
TNM classification
Anti-PD1
BRAFV600E
Biliopancreatic diversion
Dabrafenib
Assisted reproductive techniques
Resistance
ALK
Bariatric surgery
BRAF
Lung adenocarcinoma
Anti-Tumor pharmacology
Immunotherapy
Prognostic
Trametinib
Acute generalized exanthematous pustulosis
ALK rearrangement
Melanoma
BRAFV600E mutation
Biomarkers
Allelic imbalance
BRAFV600-mutant melanoma
Targeted therapy
Adverse events
Wnt
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Cancer
Circulating tumor DNA
Circulating cell-free DNA
Adjuvant
ADN tumoral circulant
Beta-catenin
Anti-CTLA-4
Prognosis
Polyomavirus
Body mass index
Osimertinib
Advanced melanoma
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Antibody-drug conjugate
Anti-PD1 blockade
Adjuvant FOLFOX
Follow-up
AZD9291
Prevention
BRAF V600E
Antineoplastic agents
Bisphosphonates
Metastatic cSCC
Cutaneous squamous cell carcinoma
Molecular targeted therapies
Immune checkpoint inhibitor
Merkel cell carcinoma
Anti-PD-1
Abdominal pain
Histiocytosis
Colorectal carcinoma
Metastatic
Plasma
Colon cancer
Treatment
Advanced
Locally advanced
Androgen insensitivity
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Children
EGFR
Immunomodulation
Biomarkers Colonic neoplasms Machine learning Prognosis Tumour infiltrating lymphocytes
Radiotherapy
Chemotherapy
Sonic Hedgehog
Mesenchymal stromal cells
Invasive cutaneous squamous cell carcinoma